840 completed, 205 unknown, 164 terminated, 153 active not recruiting. 906 Phase 2, 442 Phase 3, 311 Phase 1, 61 Not applicable, 28 Phase 4.
Follow Doxorubicin: new trials by email Literature Review of Doxorubicin trials Research Report on Doxorubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma DT-7012, Doxorubicin - Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS) | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 80 | 2027-02-01 | 2026-09-15 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma Doxorubicin - Sarcoma | Phase 2 | Recruiting | University of Colorado, Denver | 20 | 2026-12-01 | 2026-02-05 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies PM54, Irinotecan, Doxorubicin - Advanced Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | PharmaMar | 231 | 2026-11-12 | 2026-09-24 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma UTD2 + tislelizumab + doxorubicin - Soft Tissue Sarcoma (STS), Utidelone | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 49 | 2026-10-18 | 2026-09-25 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-10-01 | 2026-09-04 |
| Cardioprotection Effect of Linagliptin Doxorubicin, Empaglifloz 5 mg orally once daily - Cardiotoxicity | Phase 3 | Not yet recruiting | Tanta University | 140 | 2026-10-01 | 2026-10-15 |
| US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 32 | 2026-10-01 | 2026-10-07 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC Carboplatin, Docetaxel, Doxorubicin - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-09-01 | 2026-08-04 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-08-31 | 2026-07-27 |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
Showing 20 of 1618. Sign in to see all of them.
Breast Neoplasms (297) · Lymphoma (205) · Lymphoma, Large B-Cell, Diffuse (172) · Sarcoma (143) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (110) · Hodgkin Disease (85) · Lymphoma, Non-Hodgkin (81) · Burkitt Lymphoma (70) · Lymphoma, Follicular (64) · Leukemia (58) · Triple Negative Breast Neoplasms (53) · Ovarian Neoplasms (52) · Neoplasms (50) · Lymphoma, Mantle-Cell (48) · Carcinoma, Hepatocellular (47)
National Cancer Institute (NCI) (123) · M.D. Anderson Cancer Center (83) · Children's Oncology Group (68) · Memorial Sloan Kettering Cancer Center (36) · Hoffmann-La Roche (33) · SWOG Cancer Research Network (31) · St. Jude Children's Research Hospital (25) · European Organisation for Research and Treatment of Cancer - EORTC (23) · Alliance for Clinical Trials in Oncology (21) · Dana-Farber Cancer Institute (20) · University of Washington (19) · Merck Sharp & Dohme LLC (16) · NSABP Foundation Inc (15) · City of Hope Medical Center (14) · Ruijin Hospital (14)
United States (955) · Canada (211) · Italy (182) · France (171) · Germany (170) · United Kingdom (159) · China (157) · Australia (151) · Spain (151) · Belgium (109) · Netherlands (91) · Puerto Rico (89) · Switzerland (89) · Poland (87) · South Korea (80)
Norman Wolmark, MD (13) · Oliver W. Press, MD, PhD (6) · Sandra J. Horning, MD (6) · Antonio Lambiase, MD (5) · Frank Berthold, MD (5) · Saroj Vadhan-Raj, MD (5) · Andreas Engert, Prof. (4) · Dean F. Bajorin, MD (4)
PMID 40135712, PMID 37505794, PMID 31401903, PMID 39121442, PMID 41671463, PMID 40207789, PMID 22689675, PMID 27282998, PMID 29567784, PMID 32450725, PMID 33357481, PMID 37890117, PMID 39319495, PMID 40501401, PMID 24121121, PMID 24970932, PMID 26373676, PMID 35882475, PMID 37185961, PMID 38335467, PMID 38446568, PMID 16236738, PMID 16421426, PMID 16754935, PMID 17654614, PMID 19144982, PMID 19433688, PMID 19546402, PMID 20007997, PMID 20032498, PMID 20154213, PMID 20548096, PMID 20661232, PMID 21719599, PMID 22337718, PMID 22442346, PMID 22493293, PMID 22551107, PMID 23116553, PMID 23509310, PMID 23683550, PMID 23831416, PMID 24224624, PMID 24239220, PMID 24344215, PMID 24687837, PMID 24794243, PMID 25092775, PMID 25135998, PMID 25332249
U10CA180886 (40), U10CA098543 (39), U10CA032102 (31), 2023 (23), U10CA031946 (15), P30CA016672 (14), U10CA021115 (14), U10CA180868 (14), 2015 (12), U10CA180821 (12), 2009 (11), U10CA180888 (11), 2017 (10), P30CA043703 (10), P30CA033572 (9)